David Q Beversdorf1,2, Hanna E Stevens3, Karen L Jones4. 1. Departments of Radiology, Neurology, and Psychological Sciences And The Thompson Center for Neurodevelopmental Disorders, University of Missouri, Columbia, MO, USA. beversdorfd@health.missouri.edu. 2. Department of Radiology, University of Missouri, DC 069.10, One Hospital Drive, Columbia, MO, 65212, USA. beversdorfd@health.missouri.edu. 3. Departments of Psychiatry and Pediatrics, Iowa Neuroscience Institute, University of Iowa, Iowa City, IA, USA. 4. Department of Internal Medicine, Division of Rheumatology, Allergy, and Clinical Immunology, And the MIND Institute, University of California, Davis, Davis, CA, USA.
Abstract
PURPOSE OF REVIEW: While genetic factors are a major etiological contributor to autism spectrum disorder (ASD), evidence also supports a role for environmental factors. Herein, we will discuss two such factors that have been associated with a significant proportion of ASD risk: prenatal stress exposure and maternal immune dysregulation, and how sex and gender relate to these factors. RECENT FINDINGS: Recent evidence suggests that maternal stress susceptibility interacts with prenatal stress exposure to affect offspring neurodevelopment. Additionally, understanding of the impact of maternal immune dysfunction on ASD has recently been advanced by recognition of specific fetal brain proteins targeted by maternal autoantibodies, and identification of unique mid-gestational maternal immune profiles. Animal models have been developed to explore pathophysiology targeting both of these factors, with limited sex-specific effects observed. While prenatal stress and maternal immune dysregulation are associated with ASD, most cases of these prenatal exposures do not result in ASD, suggesting interaction with multiple other risks. We are beginning to understand the behavioral, pharmacopathological, and epigenetic effects related to these interactions, as well as potential mitigating factors. Sex differences of these risks have been understudied but are crucial for understanding the higher prevalence of ASD in boys. Continued growth in understanding of these mechanisms may ultimately allow for the identification of multiple potential points for prevention or intervention, and for a personalized medicine approach for this subset of environmental-associated ASD cases.
PURPOSE OF REVIEW: While genetic factors are a major etiological contributor to autism spectrum disorder (ASD), evidence also supports a role for environmental factors. Herein, we will discuss two such factors that have been associated with a significant proportion of ASD risk: prenatal stress exposure and maternal immune dysregulation, and how sex and gender relate to these factors. RECENT FINDINGS: Recent evidence suggests that maternal stress susceptibility interacts with prenatal stress exposure to affect offspring neurodevelopment. Additionally, understanding of the impact of maternal immune dysfunction on ASD has recently been advanced by recognition of specific fetal brain proteins targeted by maternal autoantibodies, and identification of unique mid-gestational maternal immune profiles. Animal models have been developed to explore pathophysiology targeting both of these factors, with limited sex-specific effects observed. While prenatal stress and maternal immune dysregulation are associated with ASD, most cases of these prenatal exposures do not result in ASD, suggesting interaction with multiple other risks. We are beginning to understand the behavioral, pharmacopathological, and epigenetic effects related to these interactions, as well as potential mitigating factors. Sex differences of these risks have been understudied but are crucial for understanding the higher prevalence of ASD in boys. Continued growth in understanding of these mechanisms may ultimately allow for the identification of multiple potential points for prevention or intervention, and for a personalized medicine approach for this subset of environmental-associated ASD cases.
Authors: Susan L Connors; Dorothy E Crowell; Charles G Eberhart; Joshua Copeland; Craig J Newschaffer; Sarah J Spence; Andrew W Zimmerman Journal: J Child Neurol Date: 2005-11 Impact factor: 1.987
Authors: E H Cook; R Courchesne; C Lord; N J Cox; S Yan; A Lincoln; R Haas; E Courchesne; B L Leventhal Journal: Mol Psychiatry Date: 1997-05 Impact factor: 15.992
Authors: Jeffrey M Denney; Edward L Nelson; Pathik D Wadhwa; Thaddeus P Waters; Leny Mathew; Esther K Chung; Robert L Goldenberg; Jennifer F Culhane Journal: Cytokine Date: 2010-11-30 Impact factor: 3.861
Authors: Andrew W Zimmerman; Susan L Connors; Karla J Matteson; Li-Ching Lee; Harvey S Singer; Julian A Castaneda; David A Pearce Journal: Brain Behav Immun Date: 2006-10-06 Impact factor: 7.217
Authors: Pablo R Moya; Jens R Wendland; Jennifer Salemme; Ruby L Fried; Dennis L Murphy Journal: Int J Neuropsychopharmacol Date: 2012-05-08 Impact factor: 5.176
Authors: Loren A Martin; Paul Ashwood; Daniel Braunschweig; Maricel Cabanlit; Judy Van de Water; David G Amaral Journal: Brain Behav Immun Date: 2008-02-08 Impact factor: 7.217
Authors: Özgür Genç; Joon-Yong An; Richard D Fetter; Yelena Kulik; Giulia Zunino; Stephan J Sanders; Graeme W Davis Journal: Elife Date: 2020-07-01 Impact factor: 8.140
Authors: Bibiana K Y Wong; Jaclyn B Murry; Rajesh Ramakrishnan; Fang He; Alfred Balasa; Gary R Stinnett; Steen E Pedersen; Robia G Pautler; Ignatia B Van den Veyver Journal: PLoS One Date: 2019-11-08 Impact factor: 3.240
Authors: Helen J Chen; Adrienne M Antonson; Therese A Rajasekera; Jenna M Patterson; Michael T Bailey; Tamar L Gur Journal: Transl Psychiatry Date: 2020-06-16 Impact factor: 6.222